+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The place of estramustine in the treatment of prostate cancer



The place of estramustine in the treatment of prostate cancer



Orvosi Hetilap 146(12): 553-557



Prostate cancer is a dynamic disease. Androgen ablation is palliative, and does not cure advanced prostate cancer. The hormone-sensitive cells die, and the hormone-resistant cells come into excess; the disease then progresses, which results in a deterioration of the condition of the patient. The theoretical basis of the curing strategy is the fact that the prostate tumour itself changes during the progression; the molecular determinants of the resistance are present in the varying stages of the disease. The treatment of advanced prostate cancer remains unsolved; it is a well-known fact that a hormone-resistant state develops after the primary treatment forms (androgen withdrawal). The drug of choice for the secondary treatment is estramustine. This can be utilized as monotherapy or in combination. In the present study, the results of estramustine treatment of 79 patients with advanced prostate cancer were evaluated. The preparation, known and clinically applied for more than 20 years, was studied in 12 centres. The mean prostate-specific antigen level improved for 6 months, but rose from the 9th month on. The improvement in the subjective condition of the patients paralleled the change in the prostate-specific antigen level. The shortness of the improvement was a consequence of the very high prostate-specific antigen level and the poor general condition. Estramustine administration is recommended when the prostate-specific antigen level becomes more than doubled following the primary treatment. At a starting prostate-specific antigen level of >100 ng/ml, the treatment leads to total androgen blockade. If the prostate-specific antigen level has not decreased after treatment for 3 months, the secondary strategy is to apply chemotherapy.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 050692273

Download citation: RISBibTeXText

PMID: 15853064


Related references

Administration of estramustine in response to changes in the prostate-specific antigen and Karnofsky index in the treatment of prostate cancer. In Vivo 19(4): 787-792, 2005

Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Clinical Genitourinary Cancer 4(4): 287-292, 2006

Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience. Bmc Urology 12: 3-3, 2012

Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with hormone escaped prostate cancer. European Journal of Cancer 35(SUPPL 4): S342, Sept, 1999

Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: Feasibility and preliminary results. International Journal of Radiation Oncology Biology Physics 49(3): 699-703, March 1, 2001

Rectal palpation and transrectal fine needle aspiration of the prostate in the monitoring of prostate cancer a study of 59 patients during treatment with estramustine phosphate or estrogens. Prostate 15(4): 327-334, 1989

Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group. Journal of Urology 153(5): 1580-1586, 1995

Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with hormone escaped progressive metastatic prostate cancer. Anticancer Research 18(6C): 4823, 1998

Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. British Journal of Cancer 90(1): 100-105, 2004

The treatment of disseminated prostate cancer with estramustine. Australian and New Zealand Journal of Surgery 62(11): 871-873, 2010

Estramustine phosphate vs diethylstilbestrol in the treatment of stage D prostate cancer. Progress in Clinical and Biological Research 303: 177-186, 1989

Estramustine-based combinations in the treatment of advanced prostate cancer. Cancer Investigation 17(SUPPL 1): 57-58, 1999

Treatment of hormone-refractory prostate cancer with estramustine phosphate. Actas Urologicas Espanolas 15(5): 421-424, 1991

Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865). Journal of Urology 150(6): 1840-1844, 1993